The lawsuit contends that Celsius Holdings failed to adequately disclose cardiac risks linked to Alani Nu products. Furthermore, the complaint alleges that by targeting consumers under the age of 18, the company exposed a demographic particularly vulnerable to these health hazards. These omissions, the suit claims, created significant risks for the company’s reputation and financial health that were not transparent to the public during the class period.

Shareholders who wish to serve as lead plaintiff must file their motion with the court no later than November 3, 2026. While the legal action is currently underway, no class has yet been certified. Investors are not required to take action to remain potential class members, and serving as a lead plaintiff is not a prerequisite for participating in any future financial recovery. Those choosing to participate can retain their own counsel or join the existing action via the Rosen Law Firm.